The circulating tumor cells market size has grown rapidly in recent years. It will grow from $11.9 billion in 2024 to $13.37 billion in 2025 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to cancer incidence and prevalence, clinical utility in cancer staging, emergence of liquid biopsy, patient demand for minimally invasive tests, regulatory support for liquid biopsies, focus on early cancer detection.
The circulating tumor cells market size is expected to see rapid growth in the next few years. It will grow to $21.68 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to point-of-care CTC testing, adoption of microfluidics, focus on rare cancer types, standardization of CTC assays, expansion of CTC-based clinical trials, economic and emerging market growth. Major trends in the forecast period include innovations in CTC isolation techniques, government funding for CTC research, advancements in CTC detection technologies, liquid biopsy for cancer monitoring, integration with single-cell analysis, technological convergence with artificial intelligence (AI).
The increasing incidence of cancer is expected to drive the growth of the circulating tumor cells market in the future. Cancer is a disease characterized by the uncontrolled growth of certain body cells, which can spread to other areas. Circulating tumor cells are utilized for the early detection and diagnosis of cancer, thereby contributing to the expansion of the circulating tumor cells market as cancer cases rise. For example, in January 2023, the American Cancer Society Journals, a US-based voluntary health organization, projected that 1,958,310 new cancer cases would be diagnosed in the United States, with 609,820 expected cancer-related deaths. Thus, the rising incidence of cancer is fueling the growth of the circulating tumor cells market.
The increasing adoption of circulating tumor cells analysis in clinical trials is poised to be a significant driver for the market's growth. Clinical trials, essential for assessing the safety and efficacy of new medical treatments, benefit from the integration of circulating tumor cells (CTC) analysis. This integration enhances the ability to evaluate treatment response, enable early detection and monitoring, tailor interventions to specific patient profiles, and overall, improve the efficiency and validation of clinical endpoints. As of May 2023, ClinicalTrials.gov reported 452,604 registered clinical studies, with 64,838 actively seeking participants. This surge in clinical trials, up from 365,000 registered trials in 2021, underscores the increasing adoption of circulating tumor cells analysis in research. Consequently, the growing integration of CTC analysis in clinical trials is a key driver propelling the circulating tumor cells market.
Product innovations are a significant trend gaining traction in the circulating tumor cells market. Major companies in this sector are concentrating on developing innovative products to bolster their market position. For example, in June 2024, Bio-Rad Laboratories, Inc., a US-based medical laboratory, introduced the Celselect Slides 2.0. This product is designed to improve the capture of rare cells and circulating tumor cells (CTCs), thereby enhancing the accuracy and efficiency of cell analysis for both clinical and research applications.
Major players in the circulating tumor cells market are strategically focusing on the development of innovative products, particularly in the domain of oncology liquid biopsy, to drive revenue growth. Oncology liquid biopsy involves a minimally invasive or non-invasive technique for detecting and monitoring disease biomarkers present in bodily fluids such as blood, urine, and sputum. A case in point is BillionToOne Inc., a prominent US-based biotech company specializing in molecular diagnostics. In June 2022, the company introduced oncology liquid biopsy products, namely NorthStar Select and NorthStar Response. NorthStar Select is a comprehensive somatic mutation profiling panel designed for cancer, utilizing BillionToOne's unique molecular counting method, Quantitative Counting Templates (QCTs), to identify actionable mutations with a notable limit of detection. On the other hand, NorthStar Response is a tissue-neutral, methylation-based treatment response monitoring test, providing precise estimates of circulating tumor DNA (ctDNA) methylation burden through molecular counting technologies.
In August 2023, Cell Microsystems, a US-based biotechnology company, acquired Fluxion Biosciences for an undisclosed amount. This acquisition is intended to strengthen Cell Microsystems' capabilities in cell analysis and offer advanced solutions for both research and clinical applications. Fluxion Biosciences, also based in the US, specializes in technologies for isolating and analyzing circulating tumor cells (CTCs).
Major companies operating in the circulating tumor cells market include Precision Medicine Group LLC, Bio-Techne Corporation, BIOCEPT Inc., Creativ MicroTech Inc., Fluxion Biosciences Inc., Ikonisys Inc., Qiagen N.V., ScreenCell SAS, STEMCELL Technologies Inc., Sysmex Corporation, Aviva Biosciences Corporation, LungLife AI Inc., Miltenyi Biotec GmbH, Menarini Silicon Biosystems S.p.A., Canopus Bioscience Ltd., IVDiagnostics Inc., BioFluidica Inc., Biolidics Limited, Rarecells Diagnostics SAS, LineaRx Inc., Thermo Fisher Scientific Inc., Greiner Bio-One International GmbH, Stanford Research Institute International, Agilent Technologies Inc., Resolution Bioscience Inc., Cynvenio Biosystems Inc., ApoCell Inc., Clearbridge BioMedics Pte. Ltd., Celsee Inc., RareCyte Inc., On-chip Biotechnologies Co. Ltd.
North America was the largest region in the circulating tumor cells market in 2024. Asia-Pacific is expected to be the fastest-growing region in the circulating tumor cells market during the forecast period. The regions covered in the circulating tumor cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the circulating tumor cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Circulating tumor cells (CTCs) represent solid tumor-derived cells that have detached from the primary tumor and entered the bloodstream, providing valuable diagnostic and prognostic information for cancer.
The primary products related to circulating tumor cells encompass kits and reagents, along with blood collection tubes and devices or systems. Kits and reagents constitute a comprehensive set of consumables comprising elements such as a blood specimen separator, proprietary microfluidic capture chip, CTC enrichment, and immunostaining reagents. These products are utilized for collecting various specimens from the human body, including blood, bone marrow, and other bodily fluids. They leverage different technologies such as CTC enrichment, detection, and analysis, facilitating applications in clinical or liquid biopsy procedures, as well as in research endeavors.
The circulating tumor cells market research report is one of a series of new reports that provides circulating tumor cells market statistics, including circulating tumor cells industry global market size, regional shares, competitors with a circulating tumor cells market share, detailed circulating tumor cells market segments, market trends and opportunities, and any further data you may need to thrive in the circulating tumor cells industry. This circulating tumor cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The circulating tumor cells market consists of sales of clinical samples, KRT7, PSMA positive cells, and TTF-1 positive. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The circulating tumor cells market size is expected to see rapid growth in the next few years. It will grow to $21.68 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to point-of-care CTC testing, adoption of microfluidics, focus on rare cancer types, standardization of CTC assays, expansion of CTC-based clinical trials, economic and emerging market growth. Major trends in the forecast period include innovations in CTC isolation techniques, government funding for CTC research, advancements in CTC detection technologies, liquid biopsy for cancer monitoring, integration with single-cell analysis, technological convergence with artificial intelligence (AI).
The increasing incidence of cancer is expected to drive the growth of the circulating tumor cells market in the future. Cancer is a disease characterized by the uncontrolled growth of certain body cells, which can spread to other areas. Circulating tumor cells are utilized for the early detection and diagnosis of cancer, thereby contributing to the expansion of the circulating tumor cells market as cancer cases rise. For example, in January 2023, the American Cancer Society Journals, a US-based voluntary health organization, projected that 1,958,310 new cancer cases would be diagnosed in the United States, with 609,820 expected cancer-related deaths. Thus, the rising incidence of cancer is fueling the growth of the circulating tumor cells market.
The increasing adoption of circulating tumor cells analysis in clinical trials is poised to be a significant driver for the market's growth. Clinical trials, essential for assessing the safety and efficacy of new medical treatments, benefit from the integration of circulating tumor cells (CTC) analysis. This integration enhances the ability to evaluate treatment response, enable early detection and monitoring, tailor interventions to specific patient profiles, and overall, improve the efficiency and validation of clinical endpoints. As of May 2023, ClinicalTrials.gov reported 452,604 registered clinical studies, with 64,838 actively seeking participants. This surge in clinical trials, up from 365,000 registered trials in 2021, underscores the increasing adoption of circulating tumor cells analysis in research. Consequently, the growing integration of CTC analysis in clinical trials is a key driver propelling the circulating tumor cells market.
Product innovations are a significant trend gaining traction in the circulating tumor cells market. Major companies in this sector are concentrating on developing innovative products to bolster their market position. For example, in June 2024, Bio-Rad Laboratories, Inc., a US-based medical laboratory, introduced the Celselect Slides 2.0. This product is designed to improve the capture of rare cells and circulating tumor cells (CTCs), thereby enhancing the accuracy and efficiency of cell analysis for both clinical and research applications.
Major players in the circulating tumor cells market are strategically focusing on the development of innovative products, particularly in the domain of oncology liquid biopsy, to drive revenue growth. Oncology liquid biopsy involves a minimally invasive or non-invasive technique for detecting and monitoring disease biomarkers present in bodily fluids such as blood, urine, and sputum. A case in point is BillionToOne Inc., a prominent US-based biotech company specializing in molecular diagnostics. In June 2022, the company introduced oncology liquid biopsy products, namely NorthStar Select and NorthStar Response. NorthStar Select is a comprehensive somatic mutation profiling panel designed for cancer, utilizing BillionToOne's unique molecular counting method, Quantitative Counting Templates (QCTs), to identify actionable mutations with a notable limit of detection. On the other hand, NorthStar Response is a tissue-neutral, methylation-based treatment response monitoring test, providing precise estimates of circulating tumor DNA (ctDNA) methylation burden through molecular counting technologies.
In August 2023, Cell Microsystems, a US-based biotechnology company, acquired Fluxion Biosciences for an undisclosed amount. This acquisition is intended to strengthen Cell Microsystems' capabilities in cell analysis and offer advanced solutions for both research and clinical applications. Fluxion Biosciences, also based in the US, specializes in technologies for isolating and analyzing circulating tumor cells (CTCs).
Major companies operating in the circulating tumor cells market include Precision Medicine Group LLC, Bio-Techne Corporation, BIOCEPT Inc., Creativ MicroTech Inc., Fluxion Biosciences Inc., Ikonisys Inc., Qiagen N.V., ScreenCell SAS, STEMCELL Technologies Inc., Sysmex Corporation, Aviva Biosciences Corporation, LungLife AI Inc., Miltenyi Biotec GmbH, Menarini Silicon Biosystems S.p.A., Canopus Bioscience Ltd., IVDiagnostics Inc., BioFluidica Inc., Biolidics Limited, Rarecells Diagnostics SAS, LineaRx Inc., Thermo Fisher Scientific Inc., Greiner Bio-One International GmbH, Stanford Research Institute International, Agilent Technologies Inc., Resolution Bioscience Inc., Cynvenio Biosystems Inc., ApoCell Inc., Clearbridge BioMedics Pte. Ltd., Celsee Inc., RareCyte Inc., On-chip Biotechnologies Co. Ltd.
North America was the largest region in the circulating tumor cells market in 2024. Asia-Pacific is expected to be the fastest-growing region in the circulating tumor cells market during the forecast period. The regions covered in the circulating tumor cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the circulating tumor cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Circulating tumor cells (CTCs) represent solid tumor-derived cells that have detached from the primary tumor and entered the bloodstream, providing valuable diagnostic and prognostic information for cancer.
The primary products related to circulating tumor cells encompass kits and reagents, along with blood collection tubes and devices or systems. Kits and reagents constitute a comprehensive set of consumables comprising elements such as a blood specimen separator, proprietary microfluidic capture chip, CTC enrichment, and immunostaining reagents. These products are utilized for collecting various specimens from the human body, including blood, bone marrow, and other bodily fluids. They leverage different technologies such as CTC enrichment, detection, and analysis, facilitating applications in clinical or liquid biopsy procedures, as well as in research endeavors.
The circulating tumor cells market research report is one of a series of new reports that provides circulating tumor cells market statistics, including circulating tumor cells industry global market size, regional shares, competitors with a circulating tumor cells market share, detailed circulating tumor cells market segments, market trends and opportunities, and any further data you may need to thrive in the circulating tumor cells industry. This circulating tumor cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The circulating tumor cells market consists of sales of clinical samples, KRT7, PSMA positive cells, and TTF-1 positive. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Circulating Tumor Cells Market Characteristics3. Circulating Tumor Cells Market Trends and Strategies4. Circulating Tumor Cells Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Circulating Tumor Cells Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Circulating Tumor Cells Market34. Recent Developments in the Circulating Tumor Cells Market
5. Global Circulating Tumor Cells Growth Analysis and Strategic Analysis Framework
6. Circulating Tumor Cells Market Segmentation
7. Circulating Tumor Cells Market Regional and Country Analysis
8. Asia-Pacific Circulating Tumor Cells Market
9. China Circulating Tumor Cells Market
10. India Circulating Tumor Cells Market
11. Japan Circulating Tumor Cells Market
12. Australia Circulating Tumor Cells Market
13. Indonesia Circulating Tumor Cells Market
14. South Korea Circulating Tumor Cells Market
15. Western Europe Circulating Tumor Cells Market
16. UK Circulating Tumor Cells Market
17. Germany Circulating Tumor Cells Market
18. France Circulating Tumor Cells Market
19. Italy Circulating Tumor Cells Market
20. Spain Circulating Tumor Cells Market
21. Eastern Europe Circulating Tumor Cells Market
22. Russia Circulating Tumor Cells Market
23. North America Circulating Tumor Cells Market
24. USA Circulating Tumor Cells Market
25. Canada Circulating Tumor Cells Market
26. South America Circulating Tumor Cells Market
27. Brazil Circulating Tumor Cells Market
28. Middle East Circulating Tumor Cells Market
29. Africa Circulating Tumor Cells Market
30. Circulating Tumor Cells Market Competitive Landscape and Company Profiles
31. Circulating Tumor Cells Market Other Major and Innovative Companies
35. Circulating Tumor Cells Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Circulating Tumor Cells Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on circulating tumor cells market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for circulating tumor cells ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The circulating tumor cells market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- the market characteristics section of the report defines and explains the market.
- the market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- the forecasts are made after considering the major factors currently impacting the market. These include:
- the forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- the regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- the competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- the trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Product: Kits and Reagents; Blood Collection Tubes; Devices or Systems2) by Technology: CTC Enrichment; CTC Detection; CTC Analysis
3) by Specimen: Blood; Bone Marrow; Other Body Fluids
4) by Application: Clinical or Liquid Biopsy; Research
Subsegments:
1) by Kits and Reagents: Cell Enrichment Kits; Detection Kits; Nucleic Acid Isolation Kits2) by Blood Collection Tubes: Standard Blood Collection Tubes; Specialized Blood Collection Tubes
3) by Devices or Systems: Microfluidic Devices; Automated Cell Capture Systems; Imaging Systems
Key Companies Mentioned: Precision Medicine Group LLC; Bio-Techne Corporation; BIOCEPT Inc.; Creativ MicroTech Inc.; Fluxion Biosciences Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Circulating Tumor Cells market report include:- Precision Medicine Group LLC
- Bio-Techne Corporation
- BIOCEPT Inc.
- Creativ MicroTech Inc.
- Fluxion Biosciences Inc.
- Ikonisys Inc.
- Qiagen N.V.
- ScreenCell SAS
- STEMCELL Technologies Inc.
- Sysmex Corporation
- Aviva Biosciences Corporation
- LungLife AI Inc.
- Miltenyi Biotec GmbH
- Menarini Silicon Biosystems S.p.A.
- Canopus Bioscience Ltd.
- IVDiagnostics Inc.
- BioFluidica Inc.
- Biolidics Limited
- Rarecells Diagnostics SAS
- LineaRx Inc.
- Thermo Fisher Scientific Inc.
- Greiner Bio-One International GmbH
- Stanford Research Institute International
- Agilent Technologies Inc.
- Resolution Bioscience Inc.
- Cynvenio Biosystems Inc.
- ApoCell Inc.
- Clearbridge BioMedics Pte. Ltd.
- Celsee Inc.
- RareCyte Inc.
- On-chip Biotechnologies Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 13.37 Billion |
| Forecasted Market Value ( USD | $ 21.68 Billion |
| Compound Annual Growth Rate | 12.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 32 |
